view the 2018 final subspecialty day program -...

FINAL PROGRAM ASCRS GLAUCOMA DAY: LEVEL 2, ROOM 207AB

CORNEA DAY: LEVEL 3, BALLROOM C

ASCRS REFRACTIVE DAY: LEVEL 3, BALLROOM AB

FRIDAY, APRIL 13, 2018 | WASHINGTON, DCASCRSRefractiveDay.org | ASCRSGlaucomaDay.org | CorneaDay.org

© 2018 Allergan. All rights reserved. All trademarks are the property of their respective owners. Presentation times and speakers are subject to change. These presentations are not affiliated with the official program of ASCRS 2018. UNB113395 02/18 173484

AT ALLERGAN BOOTH 1024

Expert Lecture Series

Saturday, April 14, 2018

9:30 AM The Science Behind Neurostimulation and Ophthalmology Richard Adler, MD, FACS

10:00 AM Lowering IOP in the Real World Savak Teymoorian, MD

10:30 AM Mastering DMEK: Top 10 Surgical Pearls Neda Shamie, MD

11:00 AM A Minimally Invasive Approach to IOP Control Davinder Grover, MD

11:30 AM The Science Behind Neurostimulation and Ophthalmology John Sheppard, MD, MMSc

12:30 PM Nasty Cataracts: Prevention and Management of Complications Robert Osher, MD

1:00 PM A Minimally Invasive Approach to IOP Control Arsham Sheybani, MD

1:30 PM Techniques for Your Surgical Presbyopic Patient George Waring IV, MD

2:00 PM Strategies for the Rock-Hard Nucleus David Chang, MD

2:30 PM The Science Behind Neurostimulation and Ophthalmology Preeya Gupta, MD

3:00 PM A Minimally Invasive Approach to IOP Control Manjool Shah, MD

3:30 PM New Techniques and Technologies in Cataract Surgery Eric Donnenfeld, MD, FACS

Sunday, April 15, 2018

9:30 AM A Minimally Invasive Approach to IOP Control Arsham Sheybani, MD

10:00 AM The Science Behind Neurostimulation and Ophthalmology Preeya Gupta, MD

10:30 AM Lowering IOP in the Real World Savak Teymoorian, MD

11:30 AM A Minimally Invasive Approach to IOP Control Nathan Radcliffe, MD

12:00 PM You’ll Never Believe What Happened to Me in the OR Today! Pearls for Mastering Complicated Cases Lisa Nijm, MD

1:00 PM Understanding the Signs and Symptoms Disconnect Richard Adler, MD, FACS

1:30 PM A Minimally Invasive Approach to IOP Control Robert Noecker, MD

2:00 PM Mastering DALK: Top 10 Surgical Pearls Neda Shamie, MD

3:00 PM The Science Behind Neurostimulation and Ophthalmology John Sheppard, MD, MMSc

3:30 PM A Minimally Invasive Approach to IOP Control Inder Paul Singh, MD

EVOLVING CONCEPTS IN EYE CARE

Visit Booth 1024

ANOTHER PROGRAM OF EXCELLENCE IN EDUCATION FROM ALLERGAN

GLAUCOMA DAY AGENDA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5-6

Faculty . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7

About ASCRS Glaucoma Day . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8

History/ASCRS Glaucoma Clinical Committee . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8

Stephen A . Obstbaum, MD, Honored Lecture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9

Reay of Hope Award Winners . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9

Continuing Medical Education . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11

Financial Interest Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12-14

CORNEA DAY AGENDA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17-18

Faculty . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19



REFRACTIVE DAY AGENDA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30-31

Faculty . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32



EXHIBITORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43

TABLE OF CONTENTS

GLAUCOMA DAY

INTRODUCING VYZULTANow available in pharmacies nationwide.

VYZULTA and the V design are trademarks of Bausch & Lomb Incorporated or its affi liates.©2017 Bausch & Lomb Incorporated. All rights reserved. VYZ.0360.USA.17

For more information, visit vyzultanow.com

Subspecialty Day Final Program | 5

7:00-8:00 a .m . Continental Breakfast with Exhibitors

8:00 a .m . Welcome

Douglas J. Rhee, MD

8:05–9:05 a .m . Joint ASCRS/AGS Symposium Suturing and Gluing within the Anterior Segment

Moderators: Leon W. Herndon Jr., MD Sayoko E. Moroi, MD, PhD

8:05 a.m. PCIOL Without Capsular Support: Anchor to Sclera or Iris? Brian A. Francis, MD, MS

8:13 a.m. Iris Defect Repair and Pupilloplasty Shakeel R. Shareef, MD

8:21 a.m. Drainage Implants: Suture or Glue Robert J. Noecker, MD, MBA

8:29 a.m. Suturing or Gluing the Corneal Wound Leon W. Herndon Jr., MD

8:37 a.m. Conjunctival Closure for Glaucoma Constance O. Okeke, MD, MSCE

8:45 a.m. Closure of Cyclodialysis Cleft Shane J. Havens, MD

8:53 a.m. Panel Discussion

9:05–10:20 a .m . Glaukomtecken: Practical Tech for the Modern Ophthalmologist

Moderators: Brian A. Francis, MD, Nathan M. Radcliffe, MD

9:05 a.m. EAGLE Study David S. Friedman, MD

9:13 a.m. ABCs of OCT Brian A. Francis, MD

9:21 a.m. Pearls for Visual Fields Nathan M. Radcliffe, MD

9:29 a.m. New Angles on Imaging Vikas Chopra, MD

IOP on Fire: Uveitis and Glaucoma Mini-Symposium

9:37 a.m. Glaucoma and Uveitis Ramya N. Swamy, MD

9:57 a.m. Uveitis Panel Discussion

Patient-Centric Tech

10:01 a.m. Home and 24-Hour Tonometry Kuldev Singh, MD, MPH

10:09 a.m. Apps for Glaucoma Nathan M. Radcliffe, MD

10:20-10:40 a.m. Break with Exhibitors

10:40-10:55 a .m . International Guest Speaker

Tarek M. Shaarawy, MD, MSc

10:55-11:50 a .m . Medications and Lasers: Practical Concepts for Enhancing Glaucoma Care

Moderators: Jacob W. Brubaker, MD Robert J. Noecker, MD, MBA

Part I: Medications

10:55 a.m. Oldies but Goodies: Review of Older Medications Brian A. Francis, MD

11:01 a.m. New Kids on the Block: New Drops Jacob W. Brubaker, MD

11:07 a.m. Who Wants to Live Forever? Sustained Release Devesh Varma, MD

11:13 a.m. Waiting on the World to Change: Formulary Changes, Compounding, Generics Nathan M. Radcliffe, MD

GLAUCOMA DAY | AGENDA

6 | Subspecialty Day Final Program

Part II: Lasers-Point/Counterpoint

11:19 a.m. Narrow Escape Cases: What Would You Do? David S. Friedman, MD vs. Richard A. Lewis, MD

11:35 a.m. Bridging the Trans-Scleral Divide: G-probe vs. Micropulse Robert J. Noecker, MD vs. Jeffrey A. Kammer, MD

11:43 a.m. Discussion

11:50 a.m.–12:45 p.m. Lunch with Exhibitors

12:20-12:45 p .m . Café Style Discussion

Moderator: Garry P. Condon, MD

Panel: Reay H. Brown, MD, Richard A. Lewis, MD, Thomas W. Samuelson, MD, Kuldev Singh, MD, MPH

12:45-1:20 p .m . The 2018 Stephen A . Obstbaum, MD, Honored Lecture

Epic Glaucoma Care: The 20/20 Experience

Steven D. Vold, MD

1:20-2:55 p .m . Surgical Glaucoma Spotlight

Making Sense of the MIGS Revolution: A Practical Guide to the Surgical Treatment of Glaucoma

Moderators: Ike K. Ahmed MD, Paul J. Harasymowycz, MD Steven R. Sarkisian Jr., MD, Steven D. Vold, MD

1:20 p.m. Part I—Finding Your Way Through the MIGS Maze: A Personalized, Case-Based Approach and Panel Discussion

Interactive case-based panel discussion highlighting keys to successful MIGS integration

Panel: Ike K. Ahmed, MD, Paul J. Harasymowycz, MD, Cathleen M. McCabe, MD, Marlene R. Moster, MD, Karolinne M. Rocha, MD, Steven R. Sarkisian Jr., MD, and Steven D. Vold, MD

2:12 p.m. Part II—I Thought This Was Supposed to Be Easy: A Compilation of MIGS Fails and How We Fixed Them

Video cases of MIGS complications with panel discussion to navigate management

Panel: Ike K. Ahmed, MD, Paul J. Harasymowycz, MD, Marlene R. Moster, MD, Steven R. Sarkisian Jr., MD, and Steven D. Vold, MD

2:55-3:10 p.m. Break with Exhibitors

3:10-3:30 p .m . GFC Debate Re-Match 2018: Is Trabeculectomy Dead?

Referee: Steven R. Sarkisian Jr., MD

3:10 p.m. Entrance

3:12 p.m. YES, It’s Dead! Ike K. Ahmed, MD

3:20 p.m. NO, It’s Alive and Well! Douglas J. Rhee, MD

3:28 p.m. ARS Voting & Award of the Championship Belt

3:30-4:30 p .m . Video Case Presentations: Complications and a “Reay of Hope”

Moderator: Thomas D. Patrianakos, MD

Panel: Garry P. Condon, MD, Reay H. Brown, MD Nathan M. Radcliffe, MD, Steven R. Sarkisian Jr., MD

Minimally Invasive Yet Maximally Destructive Shakeel R. Shareef, MD

Surgical Pupilloplasty for Secondary Angle Closures & Urrets-Zavalia Syndrome Priya S. Narang, MD

Batman Rogério Horta, MD

Exfoliation Glaucoma/Subluxated IOL Luis Silva, MD

My Worst OR Day Marlene R. Moster, MD

ARS Voting and “Reay of Hope” Award

4:30 p.m. Program Adjourns

GLAUCOMA DAY | AGENDA


FACULTY

PROGRAM COMMITTEEDouglas J. Rhee, MD – ChairProfessor of Ophthalmology Department of Ophthalmology and Visual Sciences Case Western Reserve University School of Medicine Cleveland, Ohio

Ike K. Ahmed, MDAssistant Professor; Fellowship Director, Glaucoma & Anterior Segment Surgery Fellowship Research Director, Kensington Eye Institute University of Toronto Clinical Professor, University of Utah Medical Director, GoEyeCare Co-Medical Director, TLC Mississauga Mississauga, Toronto, Ontario, Canada

Jacob W. Brubaker, MDSacramento Eye Consultants Sacramento, California

Brian A. Francis, MD, MSProfessor of Clinical Ophthalmology Rupert and Gertrude Steiger Chair in Glaucoma Director of Glaucoma Services Doheny Eye Institute David Geffen School of Medicine, UCLA Los Angeles, California

Paul J. Harasymowycz, MD, FRCSCAssistant Professor and Chief of Glaucoma Service University of Montreal Department of Ophthalmology Montreal, Quebec, Canada

Leon W. Herndon Jr., MDProfessor of Ophthalmology Duke University School of Medicine Hillsborough, North Carolina

Marlene R. Moster, MDProfessor of Ophthalmology Thomas Jefferson University School of Medicine Attending Surgeon, Glaucoma Department Wills Eye Hospital Bala Cynwyd, Pennsylvania

Robert J. Noecker, MD, MBAAssistant Professor of Ophthalmology Yale School of Medicine Professor of Surgery Frank Netter School of Medicine Quinnipiac University Ophthalmic Consultants of Connecticut Fairfield, Connecticut

Thomas D. Patrianakos, DOChair, Department of Ophthalmology Cook County Health & Hospital System Chicago, Illinois

Nathan M. Radcliffe, MDDirector of Glaucoma Service Assistant Professor of Ophthalmology Weill Cornell Medical College New York-Presbyterian Hospital New York, New York

Steven R. Sarkisian Jr., MDGlaucoma Fellowship Director Clinical Professor University of Oklahoma College of Medicine Dean McGee Eye Institute Oklahoma City, Oklahoma

Steven D. Vold, MDVold Vision Fayetteville, Arkansas

2018 STEPHEN A. OBSTBAUM, MD HONORED LECTURERSteven D. Vold, MDVold Vision Fayetteville, Arkansas

2018 INTERNATIONAL GUEST LECTURERTarek Shaarawy, MD, MSDirector, Glaucoma Sector Head, Glaucoma Surgery Research Group Privat-Docent Geneva University Hospital Geneva, Switzerland

FACULTYReay H. Brown, MDAtlanta, Georgia

Garry P. Condon, MDSarasota, Florida

Vikas Chopra, MDPasadena, California

David S. Friedman, MD, MPH, PhDBaltimore, Maryland

Shane J. Havens, MDOmaha, Nebraska

Rogério C. Horta, MDRio de Janeiro, Brazil

Jeffrey A. Kammer, MDNashville, Tennessee

Richard A. Lewis, MDSacramento, California

Cathleen M. McCabe, MDBradenton, Florida

Sayoko E. Moroi, MDAnn Arbor, Michigan

Priya S. Narang, MDAhmedabad, India

Constance O. Okeke, MSCENorfolk, Virginia

Karolinne M. Rocha, MD, PhDCharleston, South Carolina

Thomas W. Samuelson, MDMinneapolis, Minnesota

Shakeel R. Shareef, MDRochester, New York

Kuldev Singh, MD, MPHPalo Alto, California

Ramya N. Swamy, MDBaltimore, Maryland

Devesh Varma, MD Mississauga, Ontario, Canada

GLAUCOMA DAY | FACULTY


HISTORYThe ASCRS Glaucoma Clinical Committee (Glaucoma CC) was formed in 1997 with only four members. Glaucoma programming was minimal at the ASCRS Annual Symposium and the committee set itself a goal of increasing glaucoma awareness among the membership. Led by Chairman Brad Shingleton and initial members Alan Crandall, Alan Robin, and Murray Johnstone, the Glaucoma CC began by conducting the first of five annual glaucoma practice pattern surveys that reported on ASCRS member uses of medications, lasers, and surgery. Response was high and the surveys were published each year in the Journal of Cataract and Refractive Surgery and EyeWorld magazine. More importantly, they revealed a much deeper interest in glaucoma than was originally believed and supported the need for expanded programming at the ASCRS Annual Meeting.

ASCRS Glaucoma Day 2005 was the society’s first full-day glaucoma educational program. Led by program chairs Brad Shingleton, Robert Fechtner, Jeffrey Liebmann, and Stephen Obstbaum, the first Glaucoma Day drew 245 attendees and featured sections on “Risk Assessment” and “Pearls of the Glaucoma Surgeon.” Robert Weinreb gave the first guest lecture, “The Glaucoma Continuum,” which would later be renamed in honor of former ASCRS President and glaucoma leader, Stephen Obstbaum.

In the years that followed, ASCRS Glaucoma Day became an accepted part of the Annual Meeting program. Attendance grew each year, and the Clinical Committee members continually refined the program to meet attendee needs. Under Brad Shingleton’s early direction, a section addressing “Surgical Innovations” was added. When Reay Brown assumed the chairmanship of the Committee in 2005, he developed a “Business of Glaucoma” component that included coding, patient management, and office efficiency. Glaucoma Day attendance surpassed 400 in 2008, when attendees turned out to hear Barb Smit and Rick Lewis debate “Trabeculectomy versus the New Contenders.” A surgical video complications section was also added in 2008 under Garry Condon’s leadership, and proved so popular that it remains a part of the program today.

Douglas J. Rhee, MDChairman, 2013-Present

Thomas W. Samuelson, MDChairman, 2009-2013

Reay H. Brown, MDChairman, 2005-2008

Bradford J. Shingleton, MDChairman, 1997-2004

Ike K. Ahmed, MD

Stuart F. Ball, MD

Michael S. Berlin, MD

Jabob W. Brubaker, MD

Garry P. Condon, MD

Alan S. Crandall, MD

Herbert P. Fechter, MD

Robert D. Fechtner, MD

Brian A. Francis, MD

Paul J. Harasymowycz, MD

Murray A. Johnstone, MD

Leon W. Herndon Jr., MD

Richard A. Lewis, MD

Marlene R. Moster, MD

Robert J. Noecker, MD

Michael F. Oats, MD

Thomas D. Patrianakos, MD

Nathan M. Radcliffe, MD

Adam C. Reynolds, MD

Alan L. Robin, MD

Steven R. Sarkisian Jr., MD

Tarek Shaarawy, MD, MS

Barbara A. Smit, MD, PhD

Philippe Sourdille, MD

Steven D. Vold, MD

In 2009, Thomas Samuelson succeeded Reay Brown as committee chairman, and Sam Masket delivered the first “cataract crossover” talk on presbyopia-correcting IOLs in glaucoma. The Reay of Hope Award added a humorous note to the surgical videos section, and Marlene Moster took home the inaugural trophy for the best presentation of the worst complication.

A year later, in 2010, before an audience of 540, George Spaeth gave an inspirational talk on the 10 best things he’d learned in his long career, and Murray Johnstone’s Obstbaum Lecture highlighted his 9-year quest to acquire, protect, and license a patent for the cosmetic use of a glaucoma drug.

In 2011, the ASCRS Glaucoma Clinical Committee adopted the tag line “Glaucoma in a Cataract and Refractive Context,” which clearly describes its goal of presenting glaucoma education that is both practical and meaningful for the ASCRS member. High points included Reay Brown’s delivery of his “Exploring the Adjacent Possible” Obstbaum Lecture, and Richard Lindstrom’s early descriptions of femtosecond laser refractive cataract surgery.

2012 saw the first-ever joint symposium with the American Glaucoma Society, and a “Cornea Crossover” talk by Terry Kim. Robert Stegmann’s fascinating videos were a highlight of his Obstbaum Lecture, which carried the provocative title “The Time Has Come the Walrus ”

In 2014, Douglas Rhee took the helm as committee chair, and together with his program team, assembled a series of Glaucoma Day programs that broke all previous attendance records.

Last year, in 2017, Keith Barton was chosen as the International Guest Speaker. His talk, “MIGS…For a Few Dollars More,” preceded that of 2017 Obstbaum Lecturer, Marlene R. Moster, who spoke on “The Holy Grail: Monitoring IOL 24/7.” The day was capped by a spirted mixed martial arts-themed contest between Doug Rhee and Ike Ahmed who debated “Target IOL: Should Everyone be < 13mm Hg?” All manner of personal and professional insults were employed by both combatants before audience voting declared Rhee the 2017 champion. Don’t miss the rematch this year!

ASCRS GLAUCOMA CLINICAL COMMITTEE MEMBERS 1997-2018

GLAUCOMA DAY | HISTORY


STEPHEN A. OBSTBAUM, MD, HONORED LECTUREEpic Glaucoma Care: The 20/20 Experience

STEVEN D . VOLD, MDDr. Steven Vold is an award-winning, board-certified ophthalmologist based in Northwest Arkansas with over 24 years of experience. As an innovative vision professional specializing in complex glaucoma and cataract diagnosis and treatment, as well as groundbreaking laser vision correction. Dr. Vold is known for his passion and dedication to patients, and strives to make every patient comfortable and happy with their results. He currently serves as the Chief Medical Editor of Glaucoma Today, the leading national publication for physicians, and co-founded the American-European Congress of Ophthalmic Surgery. He regularly publishes peer-reviewed journal articles, lectures on the latest techniques, and is cited in the press for his groundbreaking procedures and research. Dr. Vold has been instrumental in the development of numerous products that are now on the market based on his creative efforts.

Graduating from Concordia College in Moorhead, Minnesota with a major in Biology, Dr. Vold went on to the University of Minnesota Medical School in Minneapolis. Here, he graduated as a member of the Alpha Omega Alpha Honor Medical Society. He completed an ophthalmology residency and a glaucoma fellowship at the Northwestern University Medical School in Chicago, Illinois.

STEPHEN A. OBSTBAUM, MD, HONORED LECTURERS2017Marlene R. Moster, MDThe Holy Grail: Monitoring IOP 24/7

2016Ronald L. Fellman, MDCanal Surgery: The Big Easy or Po-Boys

2015Barbara A. Smit, MD, PhDSclemm’s Canal Surgery: the Holy Grail or Mission Impossible?

2014Thomas W. Samuelson, MDGlaucoma Management in the “Post-Renaissance” Era

2013Garry P. Condon, MDPseudoexfoliation: My Life as a “Zonulist”—What We Know, Don’t Know, and Shouldn’t Show

2012Robert Stegmann, MDThe Time Has Come the Walrus Said…To Cure Glaucoma

2011Reay H. Brown, MDInnovation in Glaucoma Surgery: Exploring the Adjacent Possible

2010Murray A. Johnstone, MDHow a Glaucoma Surgeon Revolutionized the Cosmetic Industry

2009Richard A. Lewis, MDWhat Goes Around, Comes Around: Clinical Research in Private Practice

2008Alan S. Crandall, MDThe 30-Year Journey: Combined Glaucoma from ICCE to 2.2mm

2007Bradford J. Shingleton, MDPseudoexfoliation and Phacoemulsification in 1,000 Patients: A Single Surgeon Series

2006Peng T. Khaw, PhD, FRCP, FRCS, FRCOphth, FI Biol, FRCPath, FMedSCiAdvances in Filtration Surgery

2005Robert Weinreb, MDThe Glaucoma Continu um

REAY OF HOPE AWARD WINNERS2017Elma E. Chang, MD

2016Matthew B. Schlenker, MD

2015Manjool Shah, MD

2014Ahmad Aref, MD

2013Douglas J. Rhee, MD

2012Ike K. Ahmed, MD

2011Steven D. Vold, MD

2010Steven J. Gedde, MD

2009Marlene R. Moster, MD

GLAUCOMA DAY | STEPHEN A. OBSTBAUM, MD, HONORED LECTURE

GLAUCOMA DAYASCRS gratefully acknowledges the

unrestricted educational grants received in support of this program from:

AERIE PHARMACEUTICALS, INC.

ALCON LABORATORIES, INC.

ALLERGAN

GLAUKOS CORP

NEW WORLD MEDICAL

SANTEN PHARMACEUTICALS


CONTINUING MEDICAL EDUCATION

Target AudiencePracticing ophthalmologists who care for patients with glaucoma and related disorders.

Educational ObjectivesAt the end of the activity, participants will be able to:

• Effectively evaluate current and utilize new diagnostic testing modalities to assist in the early diagnosis of the glaucoma patient and glaucoma suspect as well as disease progression

• Make treatment decisions using evidence-based recommendations and best-practices regarding the use of medical and laser therapies for the treatment of glaucoma

• Describe and evaluate phacoemulsification treatment options in patients with pre-existing open angle glaucoma

• Compare and contrast recent and emerging microinvasive glaucoma surgical (MIGS) options and integrate pearls for improving glaucoma surgical outcomes

• Make use of surgical video pearls as a means of improving understanding of glaucoma surgical challenges

Accreditation StatementThe American Society of Cataract and Refractive Surgery is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. ASCRS takes responsibility for the content, quality, and scientific integrity of this CME activity.

Designation StatementThe American Society of Cataract and Refractive Surgery designates this live activity for a maximum of 7.5 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

All CME activities approved for AMA PRA Category 1 Credit™ are valid for recognition by the European Accreditation Council for Continuing Medical Education (EACCME). Physicians not licensed in the U.S. who participate in this CME activity are eligible for AMA PRA Category 1 Credit™.

Attendees registered as exhibitors, spouses, and guests are not eligible for CME credits.

Note: All attendees must have their badges printed onsite to be verified as eligible for credit. The program evaluation and credit claim will be available online.

Claiming CreditNote: All attendees must have their badges printed onsite to be verified as eligible for credit.

The program evaluation and CME credit claim will be available electronically. You can visit the Connect & Claim stations in the convention to complete the 2018 ASCRS Glaucoma Day course evaluation and credit claim. When complete, a certificate of the continuing education credits/hours can be printed.

If you prefer, you may complete the evaluation and credit claim online through May 4, 2018. Click on the Eval & Credit Claim button within the ASCRS•ASOA Annual Meeting app or visit ASCRS.org for the link. Please remember that your badge number is needed for access to the evaluation and credit claim system. If you plan to complete your evaluation at home, please make note of your badge number. A badge look up will be available.

Notice of Off-Label Use PresentationsThis program may include presentations on drugs or devices, or uses of drugs or devices, that may not have been approved by the Food and Drug Administration (FDA) or have been approved by the FDA for specific uses only. The FDA has stated that it is the responsibility of the physician to determine the FDA clearance status of each drug or device he/she wishes to use in clinical practice. ASCRS is committed to the free exchange of medical education. Inclusion of any presentation in this program, including presentations of off-label uses, does not imply an endorsement by ASCRS of the uses, products, or techniques presented.

ADA/Special AccommodationsASCRS fully complies with the legal requirements of the Americans with Disabilities Act (ADA) and the rules and regulations thereof. ASCRS also requires ADA compliance from its contracted vendors and facilities. Any participant in this educational program who requires special accommodation or services should contact an ASCRS staff member onsite.

GLAUCOMA DAY | CONTINUING MEDICAL EDUCATION


FINANCIAL INTEREST INDEXAs a provider accredited by the Accreditation Council for Continuing Medical Education, ASCRS•ASOA must ensure balance, independence, objectivity, and scientific rigor in all its individually or jointly provided activities.

All individuals participating in a directly or jointly-provided activity must disclose any financial interest or relationship with a company that produces, markets, resells, or distributes ophthalmic products/devices/drugs or services discussed in an educational presentation or lack thereof. Financial interest can include such things as grants or research support, consultant, stockholder, member of speaker’s bureau, financial relationships held by spouse, etc.

The intent of this disclosure is to provide the Program Committee with information so they can design and implement a balanced, independent, and scientific educational activity. This Financial Interest Index Program provides information to attendees so they can make their own judgment regarding the interest or relationship and the materials presented.

CATEGORY CODE SPECIFIC FINANCIAL INTEREST

Product P I earn royalty or derive other financial gain from an ophthalmic product or service.

Investor R I have an investment interest in a company that produces, markets, resells, or distributes ophthalmic products/devices/drugs or services related to patient clinical care.

Consultant A I receive a retainer, ad hoc fees, or other consulting income from a company that produces, markets, resells, or distributes ophthalmic products/devices/drugs or services related to patient clinical care.

B I am a member of the speaker’s bureau of a company that produces, markets, resells, or distributes ophthalmic products/devices/drugs or services related to patient clinical care.

Practice Management Consultant

C I provide practice management or marketing consulting services to ophthalmic practices.

Research D My research is fully or partially funded by a company that produces, markets, resells, or distributes ophthalmic products/devices/drugs or services related to patient clinical care.

Travel E My travel expenses have been reimbursed, paid in full or subsidized, by a company that produces, markets, resells, or distributes ophthalmic products/devices/drugs or services related to patient clinical care.

Employee* Y I am a full-time employee of a company that produces, markets, resells, or distributes ophthalmic products/devices/drugs or services related to patient clinical care.

Z I am a part-time employee of a company that produces, markets, resells, or distributes ophthalmic products/devices/drugs or services related to patient clinical care.

Spouse/Partner S My spouse or partner has a financial relationship with a company that produces, markets, resells, or distributes ophthalmic products/devices/drugs or services related to patient clinical care, encompassing royalties, investment, consulting/speakers bureau, research grants, travel reimbursement or employment.

* Employee is defined as someone who receives a W-2 from a company.

GLAUCOMA DAY | FINANCIAL INTEREST INDEX


Ahmed, Ike Acucela A Aerie A Brown, Reay Allergan A Glaukos P Rhein P Transcend A

Brubaker, Jacob Aerie A, D Alcon Laboratories, Inc. A, B Allergan A, B, D Glaukos D Ivantis D New World Medical A, B

Condon, Garry Alcon A, B Allergan A Ivantis A Microsurgical Technologies A, B

Chopra, Vikas Allergan D

Francis, Brian Allergan D Beaver Visitech A Diopsys A, D Glaukos D InnFocus D Neomedix A

Friedman, David Allergan A, B For Sight Vision 5 A, B Nidek A, B Valeant A, B

Harasymowycz, Paul Alcon B Allergan B Bausch + Lomb B Glaukos B Ivantis D Johnson & Johnson Vision B

Havens, Shane None

Herndon, Leon Alcon Laboratories, Inc. B, E Glaukos B Reichert B Sight Sciences B

Horta, Rogério None

Kammer, Jeffrey Aerie A Allergan A, B Lewis, Richard Aerie Y Alcon A Allergan A AVS A Carl Zeiss Meditec A Equinox A Glaukos A Ivantis A

McCabe, Cathleen Alcon Laboratories, Inc. B, D Allergan B Bausch + Lomb B Glaukos B, D Ivantis B, D Omeros B Shire B

Moroi, Sayoko Allergan D

Moster, Marlene Aerie D Alcon Laboratories, Inc. A, D Allergan D Bausch + Lomb D Glaukos B IOP Ophthalmics B Iridex D Mobius A New World Medical D Qura A SOLX A Narang, Priya None

Noecker, Robert Aerie A Alcon A, B Allergan A, B Beaver Visitec A, B Diopsys A, B Ethis A Glaukos A, B, D Intotek A Iridex A, B, D ISP R, A Ocular Therapeutix R, A, B Polyactiva A Santen A Shire A Sun Pharma A

Okeke, Constance Glaukos D Neomedix A, B New World Medical B

Patrianakos, Thomas None



Radcliffe, Nathan Aerie A Alcon A Alimera A Allergan A Bausch + Lomb A Beaver Visitec A Glaukos A Iridex A Lumenis A New World Medical A Reichert A Transcend Medical A

Rhee, Douglas Aerie R Allergan D Glaukos D Ivantis D Merck D Sanofi A

Rocha, Karolinne Ace Vision Group A Alcon Laboratories, Inc. A Allergan A Bausch + Lomb A Johnson & Johnson Vision A

Samuelson, Thomas AcuMems A Aerie A Akorn A Alcon A Allergan A AqueSys A Bausch + Lomb A Belkin Laser A Endo Optiks A Equinox R, A Glaukos R, A

Ivantis R, A Johnson & Johnson Vision A Ocular Surgery News A PolyActiva A Santen A Shire A Transcend Medical A Veracity Innovations A Vindoco/SLACK A

Sarkisian, Steven Alcon A, B Allergan A Beaver Visitec A Glaukos A, D Katena A New World Medical R, A Omeros A Santen A Sight Sciences R, A

Shaarawy, Tarek None

Shareef, Shakeel None

Swamy, Ramya None

Silva, Luis None

Singh, Kuldev Aerie A Alcon Laboratories, Inc. A Allergan A Glaukos A InjectSense A Ivantis A KaliCare A Mynosys A Novartis A Ocular Therapeutix A Santen A Shire A

Varma, Devesh Alcon Laboratories, Inc. A Allergan A Glaukos A Johnson & Johnson Vision A Labtician A New World Medical A Vold, Steven Aerie A, D Alcon A, D Allergan B, D Alphaeon A, D AqueSys A, D Bausch + Lomb D Carl Zeiss Meditec A, D Clahoun Vision D Diopsys A Forsight Labs A, D Glaukos A, D InnFocus A, D Iridex A, D iSTAR Medical A Ivantis A, D Lumenis A Neomedix B Ocular Therapeutix A, D Ocunetics R Transcend Medical P, A, D TrueVision Systems R, A Volk Optical P


CORNEA DAY

Putting you back in the driver‘s seat.ZEISS ReLEx SMILE

Carl Zeiss Meditec, Inc. 800 342 9821 www.zeiss.com/medREL.9733 ©2018 Carl Zeiss Meditec, Inc. All copyrights reserved.

The technology is here, the time is now.

Take control with ZEISS ReLEx® SMILE, the biggest refractive surgery breakthrough in 15 years. Proven in more than a million procedures worldwide – and available in the U.S. – the revolutionary LVC technology will rev up your practice and recharge your passion for refractive surgery.

Visit ZEISS at Booth 2220 to learn more.www.zeiss.com/us/relex-smile

ZOR-043 SMILE Surgeon Print Ads M4b.indd 1 2/6/18 4:08 PM


7:00-8:00 a .m . Continental Breakfast with Exhibitors

Session I: Surgical Scenarios – Managing DMEK Disasters and Other Cornea Catastrophes

Moderators: John Berdahl, MD and Audrey Talley Rostov, MD

8:00 a.m. Welcome

8:05-8:09 a.m. DMEK (or DSEK) Disaster* Pravin Vaddavalli, MD

8:09-8:15 a.m. Panel Discussion

8:17-8:21 a.m. DMEK Dances Neda Shamie, MD


8:27-8:31 a.m. S.O.S. Save Our Stroma or Scarred for Life Leela Raju, MD


8:37-8:41 a.m. Repairing Refractive Complications Karolinne Rocha, MD


8:47-8:51 a.m. Cornea Catastrophe* Brandon Ayres, MD


8:57-9:01 a.m. Treatment for Transplant Trauma Zaina Al-Mohtaseb, MD


9:07-9:11 a.m. Keratoconus Conundrum Brandon Baartman, MD


9:17-9:21 a.m. DALK Debacle* Sumitra Khandelwal, MD


9:35-9:50 a.m. Break with Exhibitors

Session II: Smoke or Fire?

Moderators: Francis Mah, MD and Elmer Tu, MD

Section 1: Inflammatory Eye Disease

9:50 a.m. Welcome

9:55-10:05 a.m. New and Old Approaches to Immunosuppression of the Ocular Surface* Nisha Acharya, MD

10:05-10:15 a.m. Panel discussion

10:15-10:45 a.m. Cases: Scleritis Sanjay Kedhar, MD

Peripheral Ulcerative Keratitis Victor Perez, MD

Corneal melt* Esen Akpek, MD

HZO/HSV Stromal Keratitis Helen Wu, MD

Section 2: Infectious Eye Disease

10:50-11:00 a.m When Fluoroquinolones Fail: Diagnostic Approach to Atypical Corneal Infections* Sonal Tuli, MD

11:00-11:10 a.m Panel discussion

11:10-11:40 a.m Cases: Corneal Ulcer (Surgical Management)

Christopher Rapuano, MD

Resistant Bacterial Keratitis Ana Luisa Hofling-Lima, MD

Fungal Keratitis (post-surgical or de novo)Denise de Freitas, MD

Recalcitrant HSV or HZV Keratitis* James Chodosh, MD

Parasitic Keratitis Jod Mehta, MD

Collagen Crosslinking* Clara Chan, MD

11:40-12:40 p.m. Lunch with Exhibitors

*Advanced topics geared for the corneal and refractive specialist.

CORNEA DAY | AGENDA


Session III: Advances and What’s Trending in Ocular Surface

Moderators: Marjan Farid, MD, and Shahzad Mian, MD

Section 1: Understanding DED

12:40-12:45 p.m. Welcome

12:45-12:56 p.m. Corneal neuropathic pain: • How do you diagnose it?

Anat Galor, MD

• How do you treat it? Deborah Jacobs, MD

12:56-1:02 p.m. Diagnostic imaging for dry eye disease: Is it worth the cost? John Sheppard, MD

1:02-1:24 p.m. Dry eye Algorithms –Where do you start?

*DEWS 2 – Update on what’s new in definition and diagnosis Dimitri Azar, MD

*CEDARS protocol – Where do we start with diagnostics and treatment, Mark Milner, MD

*ASCRS CCC protocol – Algorithm for a quick in-office approach and what to do with the refractive patient, Terry Kim, MD

Section 2: New Treatments in DED

1:26-1:41 p.m. Featured Lecture: Role of nutritional supplements in dry eye disease, Penny Asbell, MD

1:41-1:48 p.m. Anti-inflammatories – What do we know and what’s coming? Amy Lin, MD

1:48-1:54 p.m. Nasal neurostimulation – Does this really work? Arturo Chayet, MD

1:54-2:00 p.m. Office-based treatments for MGD – What really works? Preeya Gupta, MD

Section 3: Surgical Advances in Ocular Surface Disease*

2:02-2:08 p.m. Autologous limbal stem cell transplantation – SLET Namrata Sharma, MD

2:08-2:14 p.m. Corneal Neurotonization procedure: Does it work? Christopher Hood, MD

2:14-2:20 p.m. Ex-vivo expansion of limbal stem cells: Achievable reality? Ali Djalilian, MD

2:20-2:35 p.m. Featured Lecture: Artificial corneal transplantation: What’s the future? Edward Holland, MD

2:35-2:50 p.m. Break with Exhibitors

Session IV: The Great DebateModerators: Ken Beckman, MD and Elizabeth Yeu, MD

2:50-2:55 p.m. Welcome

2:55-3:01 p.m. Cornea Crosslinking in 2018: Which age is too young or old to treat? Do eyes have to demonstrate progression for treatment? What combination treatments are out there? A. John Kanellopoulos, MD *

3:01-3:11 p.m. Panel Discussion: Ronato Ambrosio, MD, Katy Hatch, MD, Raj Rajpal, MD, Doyle Stulting, MD

3:11-3:17 p.m. Cataract Surgery and the Ectasia Patient: Evaluation of patient– Should CXL be performed? Bill Trattler, MD*

3:17-3:27 p.m. Panel Discussion: Ronato Ambrosio, MD, Katy Hatch, MD, John Kanellopous, MD, Raj Rajpal, MD, Doyle Stulting,MD

3:30-3:37 p.m. ATIOLs and the Abnormal Cornea: Management considerations for DED/ABMD/SND, Nicole Fram, MD

3:37-3:43 p.m. Panel Discussion: Jessica Ciralsky, MD, Keith Walter, MD, Bill Wiley, MD

3:45-3:51 p.m. Endothelial Disease and the Cataract: Management considerations for the patient with Fuchs’ and Cataract, Barry Lee, MD *

3:51-4:01 p.m. Panel Discussion: Winston Chamberlain, MD, Kathy Colby, MD, Rajesh Fogla, MD, Frank Price, MD

4:03-4:30 p.m. Case scenarios, Ken Beckman, MD, and Elizabeth Yeu, MD

a. Fuchs’ without edema and 2+ NSC

b. Monocular patient with 3+ corneal edema and 3+ NS cataract

4:30 p.m. Program Concludes

*Advanced topics geared for the corneal and refractive specialist.

CORNEA DAY | AGENDA


Marian Macsai, MD (Cornea Society) Francis Mah, MD (ASCRS)

Ken Beckman, MD (Cornea Society)

John Berdahl, MD (ASCRS)

Marjan Farid, MD (ASCRS)

Shahzad Mian, MD (Cornea Society)

Audrey Talley Rostov, MD (Cornea Society)

Elmer Tu, MD (Cornea Society)

Elizabeth Yeu, MD (ASCRS)

PROGRAM CHAIRS

PROGRAM PLANNING COMMITTEE

Zaina Al-Mohtaseb, MD

Nisha Acharya, MD

Esen Akepk, MD

Ronato Ambrosio, MD

Penny Asbell, MD

Brandon Ayers, MD

Dimitri Azar, MD

Brandon Baartman, MD

Winston Chamberlain, MD

Clara Chan, MD

Arturo Chayet, MD

James Chodosh, MD

Jessica Ciralsky, MD

Kathy Colby, MD

Ali Djalilian, MD

Denise de Freitas, MD

Rajesh Fogla, MD

Nicole Fram, MD

Anat Galor, MD

Preeya Gupta, MD

Katy Hatch, MD

Ana Luisa Hofling-Lima, MD

Edward Holland, MD

Christopher Hood, MD

Deborah Jacobs, MD

John Kanellopoulos, MD

Sanjay Kedhar, MD

Sumitra Khandelwal, MD

Terry Kim, MD

Barry Lee, MD

Amy Lin, MD

Jod Mehta, MD

Mark Milner, MD

Victor Perez, MD

Frank Price, MD

Raj Rajpal, MD

Leela Raju, MD

Christopher Rapuano, MD

Karolinne Rocha, MD

Neda Shamie, MD

Namrata Sharma, MD

John Sheppard, MD

Doyle Stulting, MD

William Trattler, MD

Sonal Tuli, MD

Pravin Vaddavalli, MD

Keith Walter, MD

Bill Wiley, MD

Helen Wu, MD

INVITED SPEAKERS

CORNEA DAY | FACULTY & SPEAKERS

CORNEA DAYASCRS and the Cornea Society gratefully

acknowledge the unrestricted educational grants received in support of this program from:


ALLERGAN

AVEDRO

BAUSCH + LOMB

JOHNSON & JOHNSON VISION

SHIRE



Target AudiencePracticing ophthalmologists who care for patients with cornea-related conditions.


• Evaluate how to integrate crosslinking into practice

• Compare and contrast modalities for ocular surface reconstruction

• Implement strategies to identify and efficiently manage patients with ocular surface disease/dry eye disease preoperatively

• Compare and contrast new advances in dry eye disease

• Incorporate methods and pearls to successfully perform anterior segment surgery with concurrent corneal disease

• Implement strategies to transition from DSAEK to DMEK

• Analyze the indications and surgical techniques for newer forms of lamellar keratoplasty

Accreditation StatementThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Society of Cataract and Refractive Surgery (ASCRS) and the Cornea Society. ASCRS is accredited by the ACMME to provide continuing medical education for physicians. ASCRS takes responsibility for the content, quality, and scientific integrity of this CME activity.




Note: All attendees must have their badges printed on site to be verified as eligible for credit. The program evaluation and credit claim will be available online.


The program evaluation and CME credit claim will be available electronically. You can visit the Connect & Claim stations in the convention to complete the 2018 Cornea Day course evaluation and credit claim. When complete, a certificate of the continuing education credits/hours can be printed.




CORNEA DAY | CONTINUING MEDICAL EDUCATION


















CORNEA DAY | FINANCIAL INTEREST INDEX


Acharya, Nisha None

Akpek, Esen K. Allergan D Bausch + Lomb D Gore D Medimmune A Regeneron A Shire A, D Tearlab D

Al-Mohtaseb, Zaina Alcon Laboratories, Inc. B Allergan A Ambrósio, Renato Alcon Laboratories, Inc. A Allergan A Carl Zeiss Meditec A Mediphacos A Oculus A Asbell, Penny Allergan A Kao Corporation A MC2 Therapeutics D Medscape A Novartis A, D Perrigo A Regeneron A Santen A Scientia A Senju A Shire A Valeant A, D Virtuoso A Ayres, Brandon D. Alcon Laboratories, Inc. A Allergan A Bausch + Lomb B Biotissue B Microsurgical Technology A Omeros A Azar, Dimitri None

Baartman, Brandon None

Beckman, Kenneth Alcon Laboratories, Inc. A, B Allergan A, B Avedro A Bausch + Lomb A Bruder A Calhoun R Carl Zeiss Meditec A, B EyeXpress R, A Ocular Science A Omeros A RPS R, A Shire A, B Sun Pharmaceuticals A, B TearLab A, B Berdahl, John P. Alcon Laboratories, Inc. A, E Allergan A, E Aurea Medical A Avedro B Bausch + Lomb A Calhoun / RxSight A Clarvista A DakotaSight Eye and Tissue Bank A Digisight R, A Envisia A Equinox P, R, A Glaukos A, E Iantech P, A Imprimis P, A Johnson & Johnson Vision A New World Medical A, E Ocular Surgical Data R, A Ocular Theraputix A Omega Ophthalmic R, A SightLife Surgical R, A Vance Thompson Vision R, A, Y Veracity R, A Vittamed A

Chamberlain, Winston None Chan, Clara C. Alcon Laboratories, Inc. B Allergan A, B, D Bausch + Lomb A, D Santen A, B Shire A, B TearLab D

Chayet, Arturo S. Iveena D LensGen D RVO D RxSight D Chodosh, James None

Ciralsky, Jessica B. Allergan A Johnson & Johnson Vision A Shire A Colby, Kathryn Novartis AG International A WL Gore, Inc. A de Freitas, Denise None

Djalilian, Ali R. Abbvie A Novartis A Vomaris A Farid, Marjan Allergan A Johnson & Johnson Vision A, B Shire A, B SightLife Surgical A, B TearScience A Fogla, Rajesh None

Fram, Nicole R. Accutome, Inc D Alcon Laboratories, Inc. A, B Allergan A B & L/Valeant B Carl Zeiss Meditec A Johnson & Johnson Vision A, B Notal Vision Inc. A Ocular Science R, A Omeros A RxSight, Inc. A Shire A, B SightLife Surgical R, A Sun Pharmaceuticals A



Galor, Anat Allergan B Shire A

Gupta, Preeya K. Alcon Laboratories, Inc. A Allergan A Aurea A Bio-Tissue A Johnson & Johnson Vision A Novabay A Ocular Science A Shire A TearLab A TearScience A

Hatch, Kathryn M. Avedro A Omeros A Shire A

Hofling-Lima, Ana Luisa None Holland, Edward J. Alcon Laboratories, Inc. A, B, D, E Allergan A, B, D Kala Corporation A Mati Therapeutics A, D Omeros A, B, D PRN A, D Senju Pharmaceuticals A, B, D Shire A, B TearLab A TearScience A, B Jacobs, Deborah S. BostonSight, 501(c)3 Y TECLens A Kanellopoulos, A. John A.R.C. Laser GmbH A Alcon Laboratories, Inc. A Avedro A Carl Zeiss Meditec D KeraMed, Inc. B

Kedhar, Sanjay Abbvie D Khandelwal, Sumitra S. Allergan A Omeros B Shire A TearLab D

Kim, TerryAerie Pharmaceutical A Lee, W. Barry Elsevier P Georgia Eye Bank E Shire A, B

Lin, Amy Allakos A Luchs, Jodi Aerie D Alcon Laboratories, Inc. D Allergan A, B, D, E Auven D Bausch + Lomb A, B, D, E Calhoun Vision R CXL Ophthalmics R Evolve Pharmaceuticals R Eyevance R Insightful Solutions R Ocular Sciences R, A Omega Ophthalmics R RPS R Shire A, B, D, E Sun Pharmaceuticals A, B, D, E TearLab A, B Trefoil Therapeutics R Macsai, Marian S. Abbvie A Allergan B PRN A Shire B

Mah, Francis S. Aerie A Alcon Laboratories, Inc. A, B Allergan A, B, D Avellino Labs B Bausch + Lomb A, B CoDa R, A Inversa R, A Iview D Johnson & Johnson Vision A, B, D NovaBay R, A Ocular Science R, D Ocular Therapeutix A Okogen R, A Omeros A PMN R, A PolyActiva A Shire A, B Sun Pharmaceuticals A, B Sydnexis R, A TearLab A, D

Mehta, Jod S. None

Mian, Shahzad Avellino D Milner, Mark S. Aldeyra Therapeutics D, E Allergan Pharmaceuticals A, B, E Avedro A, B, D, E Bausch + Lomb A, B, E Eleven Biotherapeutics D, E Eye Gate Pharmaceuticals D, E Eyevance Pharmaceuticals P, R, A Kala Pharmaceuticals A, D, E Omeros Corp. A Percept Technologies P, R, A Rapid Pathogen Screening, Inc R Shire Pharmaceuticals A, B, E Sun Pharmaceuticals A, B, E TearScience A, B, E Valeant Pharmaceuticals A, B, E


dmonasterio

Sticky Note

Kim, Terry Aerie Pharmaceutical


Perez, Victor L. Alcon Laboratories, Inc. A Allergan A Bausch + Lomb A, D Shire A TearLab B

Price, Francis W. Haag Streit A Interactive Medical Publishing R ReVital Vision R RxSight R Staar Surgical R Strathspey Crown R Rajpal, Rajesh K. Alcon Laboratories, Inc. A Allergan A, B, D, E Avedro R, D, E, Z Bausch + Lomb/Valeant A, B, E Calhoun Vision R Johnson & Johnson Vision A Mimetogen R, A Ocular Therapeutix A, D Omeros A RPS R Shire A, B, D, E Tear Solutions R Raju, Leela None

Rapuano, Christopher J. Allergan A Avedro A, B Bausch + Lomb B Bio-Tissue A Glaxo Smith Kline A Novartis A RPS R Shire A, B TearLab A

Rocha, Karolinne M. Ace Vision Group A Alcon Laboratories, Inc. A Allergan A Bausch + Lomb A Johnson & Johnson Vision A

Shamie, Neda Alcon Laboratories, Inc. A, B Allergan A, B, E Bausch + Lomb A, B Bio-Tissue A, B KeraLink International A, B, E Modernizing Medicine A SightLife A, B Sun Pharmaceuticals A, B Taris S Sharma, Namrata None

Sheppard, John D. AbbVie A, B, E Aerie Pharma A Alcon Laboratories, Inc. A, B, D, E Aldeyra A, D, E Allergan A, B, D, E Bausch + Lomb A, B, D, E Bio-Tissue A, B, E Clearside R, A, E EyeGate Research R, A, B, D, E Kala Pharmaceuticals A, D, E NovaBay R, A, E Omeros A, B, E Parion A, D Portage A, E Santen A, B, D, E Science Based Health A, B, E Shire A, B, D, E Sun Pharmaceuticals A, B, E TearLab R, A, B, E TearScience A, B, E Topivert A, E

Stulting, Doyle Alcon Laboratories, Inc. A Avedro A Calhoun Vision A Cambium Medical Technologies A EyeYon A Hydrolenz A Intelon A Johnson & Johnson Vision A Ocumetrics A Ophtec A Promisight A TearLab A Talley Rostov, Audrey R. Allergan A, B Bausch + Lomb A, B, D Shire B Sun Pharmaceuticals A

Trattler, William B. Alcon Laboratories, Inc. A Allergan A, B, D Alphaeon R ArcScan R Avedro A, B Bausch + Lomb A, B CXLO R Johnson & Johnson Vision A, B NovaBay B Shire A, B Sun Pharmaceuticals A, B Tu, Elmer Y. Abbvie A EBAA D Eversight D, E Thea E Tuli, Sonal None Vaddavalli, Pravin None



Walter, Keith Johnson & Johnson Vision A, B Omeros A, B Shire A, B SightLife P, E Sun Pharmaceuticals A, B Wiley, William F. Acufocus A Alcon Laboratories, Inc. B Allergan D ArcScan A Calhoun D Carl Zeiss Meditec A Clarity R Equinox R Glaukos A Imprimis P Johnson & Johnson Vision A, B, D New World Medical A Omega R, A Revision B RxSight R, B, D Wu, Helen K. Allergan A Omeros A Shire B Sun Pharmaceuticals A

Yeu, Elizabeth Alcon Laboratories, Inc. A, B Allergan A, B Bausch + Lomb A BioTissue A, B, D BVI A iOptics A, B, D Johnson & Johnson Vision A, B Kala A, D Modernizing Medicine R Ocular Science R, D Ocular Therapeutix A OcuSoft A Omeros A Science Based Health A Shire A, B Tear SCience A TearLab A, B, D TopCon D


REFRACTIVE DAY

The pinnacle of refractive performance.

Our greatest achievement yet, Contoura™ Vision outperformed even glasses and contacts.*,1

With the exceptional results for improvement in UCVA, BSCVA and visual disturbances, Contoura™ Vision Topography-Guided LASIK has taken refractive outcomes even higher.1 By enhancing the symmetry of the corneal surface, Contoura™ Vision stands alone in refractive precision — and it’s only from WaveLight®.

For additional information or to schedule a demonstration, contact your Alcon sales representative.For important safety information about this product, please refer to the adjacent page.*Post hoc analysis of postoperative UCVA compared to preoperative BSCVA of 230 eyes contained in the FDA T-CAT pivotal trial at 12 months. The primary end point evaluated changes in BSCVA.1. Results from FDA T-CAT-001 clinical study for Topography-Guided vision correction (with the 400 Hz ALLEGRETTO WAVE® Eye-Q Excimer Laser).

© 2016 Novartis 8/16 US-WVL-15-E-0287(1)

AdvancingREFRACTIVE SURGERY

WaveLight® REFRACTIVE PORTFOLIO

100697 US-WVL-15-E-0287(1) FP.indd 1 1/31/18 7:54 AM

WAVELIGHT® EXCIMER LASER SYSTEMS IMPORTANT PRODUCT INFORMATIONThis information pertains to all WaveLight® Excimer Laser Systems, including the WaveLight® ALLEGRETTO WAVE®, the ALLEGRETTO WAVE® Eye-Q and the WaveLight® EX500.

Caution: Federal (U.S.) law restricts the WaveLight® Excimer Laser Systems to sale by or on the order of a physician. Only practitioners who are experienced in the medical mangement and surgical treatment of the cornea, who have been trained in laser refractive surgery (including laser calibration and operation) should use a WaveLight® Excimer Laser System.

Indications: FDA has approved the WaveLight® Excimer Laser systems for use in laser-assisted in situ keratomileusis (LASIK) treatments for: the reduction or elimination of myopia of up to - 12.00 D and up to 6.00 D of astigmatism at the spectacle plane; the reduction or elimination of hyperopia up to + 6.00 D with and without astigmatic refractive errors up to 5.00 D at the spectacle plane, with a maximum manifest refraction spherical equivalent of + 6.00 D; • the reduction or elimination of naturally occurring mixed astigmatism of up to 6.00 D at the spectacle plane; and the wavefront-guided reduction or elimination of myopia of up to -7.00 D and up to 3.00 D of astigmatism at the spectacle plane.In addition, FDA has approved the WaveLight® ALLEGRETTO WAVE® Eye-Q Excimer Laser System, when used with the WaveLight® ALLEGRO Topolyzer® and topography-guided treatment planning software for topography-guided LASIK treatments for the reduction or elimination of up to -9.00 D of myopia, or for the reduction or elimination of myopia with astigmatism, with up to -8.00 D of myopia and up to 3.00 D of astigmatism.

The WaveLight® Excimer Laser Systems are only indicated for use in patients who are 18 years of age or older (21 years of age or older for mixed astigmatism) with documentation of a stable manifest refraction defined as ≤ 0.50 D of preoperative spherical equivalent shift over one year prior to surgery, exclusive of changes due to unmasking latent hyperopia.Contraindications: The WaveLight® Excimer Laser Systems are contraindicated for use with patients who: are pregnant or nursing; have a diagnosed collagen vascular, autoimmune or immunodeficiency disease; have been diagnosed keratoconus or if there are any clinical pictures suggestive of keratoconus; are taking isotretinoin (Accutane*) and/or amiodarone hydrochloride (Cordarone*); have severe dry eye; have corneas too thin for LASIK; have recurrent corneal erosion; have advanced glaucoma; or have uncontrolled diabetes.Warnings: The WaveLight® Excimer Laser Systems are not recommended for use with patients who have: systemic diseases likely to affect wound healing, such as connective tissue disease, insulin dependent diabetes, severe atopic disease or an immu-nocompromised status; a history of Herpes simplex or Herpes zoster keratitis; significant dry eye that is unresponsive to treatment; severe allergies; a history of glaucoma; an unreliable preoperative wavefront examination that precludes wavefront-guided treatment; or a poor quality preoperative topography map that precludes topography-guided LASIK treatment.The wavefront-guided LASIK procedure requires accurate and reliable data from the wavefront examination. Every step of every wavefront measurement that may be used as the basis for a wavefront-guided LASIK procedure must be validated by the user. Inaccurate or unreliable data from the wavefront examination will lead to an inaccurate treatment.Topography-guided LASIK requires preoperative topography maps of sufficient quality to use for planning a topography-guided LASIK treatment. Poor quality topography maps may affect the accuracy of the topography-guided LASIK treatment and may result in poor vision after topography-guided LASIK.Precautions: The safety and effectiveness of the WaveLight® Excimer Laser Systems have not been established for patients with: progressive myopia, hyperopia, astigmatism and/or mixed astigmatism, ocular disease, previous corneal or intraocular surgery, or trauma in the ablation zone; corneal abnormalities including, but not limited to, scars, irregular astigmatism and corneal warpage; residual corneal thickness after ablation of less than 250 microns due to the increased risk for corneal ectasia; pupil size below 7.0 mm after mydriatics where applied for wavefront-guided ablation planning; history of glaucoma or ocular hypertension of > 23 mmHg; taking the medications sumatriptan succinate (Imitrex*); corneal, lens and/or vitreous opacities including, but not limited to cataract; iris problems including , but not limited to, coloboma and previous iris surgery compromising proper eye tracking; or taking medications likely to affect wound healing including (but not limited to) antimetabolites.

In addition, safety and effectiveness of the WaveLight® Excimer Laser Systems have not been established for: treatments with an optical zone < 6.0 mm or > 6.5 mm in diameter, or an ablation zone > 9.0 mm in diameter; or wavefront-guided treatment targets different from emmetropia (plano) in which the wavefront calculated defocus (spherical term) has been adjusted;In the WaveLight® Excimer Laser System clinical studies, there were few subjects with cylinder amounts > 4 D and ≤ 6 D. Not all complications, adverse events, and levels of effectiveness may have been determined for this population.Pupil sizes should be evaluated under mesopic illumination conditions. Effects of treatment on vision under poor illumination cannot be predicted prior to surgery.

Adverse Events and ComplicationsMyopia: In the myopia clinical study, 0.2% (2/876) of the eyes had a lost, misplaced, or misaligned flap reported at the 1 month examination.

The following complications were reported 6 months after LASIK: 0.9% (7/818) had ghosting or double images in the operative eye; 0.1% (1/818) of the eyes had a corneal epithelial defect.Hyperopia: In the hyperopia clinical study, 0.4% (1/276) of the eyes had a retinal detachment or retinal vascular accident reported at the 3 month examination.

The following complications were reported 6 months after LASIK: 0.8% (2/262) of the eyes had a corneal epithelial defect and 0.8% (2/262) had any epithelium in the interface.Mixed Astigmatism: In the mixed astigmatism clinical study, two adverse events were reported. The first event involved a patient who postoperatively was subject to blunt trauma to the treatment eye 6 days after surgery. The patient was found to have an intact globe with no rupture, inflammation or any dislodgement of the flap. UCVA was decreased due to this event. The second event involved the treatment of an incorrect axis of astigmatism. The axis was treated at 60 degrees instead of 160 degrees.The following complications were reported 6 months after LASIK: 1.8% (2/111) of the eyes had ghosting or double images in the operative eye.Wavefront-Guided Myopia: The wavefront-guided myopia clinical study included 374 eyes treated; 188 with wavefront-guided LASIK (Study Cohort) and 186 with Wavefront Optimized® LASIK (Control Cohort). No adverse events occurred during the post-operative period of the wavefront-guided LASIK procedures. In the Control Cohort, one subject undergoing traditional LASIK had the axis of astigmatism programmed as 115 degrees instead of the actual 155 degree axis. This led to cylinder in the left eye.The following complications were reported 6 months after wavefront-guided LASIK in the Study Cohort: 1.2% (2/166) of the eyes had a corneal epithelial defect; 1.2% (2/166) had foreign body sensation; and 0.6% (1/166) had pain. No complications were reported in the Control Cohort.

Topography-Guided Myopia: There were six adverse events reported in the topography-guided myopia study. Four of the eyes experienced transient or temporary decreases in vision prior to the final 12 month follow-up visit, all of which were resolved by the final follow-up visit. One subject suffered from decreased vision in the treated eye, following blunt force trauma 4 days after surgery. One subject experienced retinal detachment, which was concluded to be unrelated to the surgical procedure.Clinical DataMyopia: The myopia clinical study included 901 eyes treated, of which 813 of 866 eligible eyes were followed for 12 months. Accountability at 3 months was 93.8%, at 6 months was 91.9%, and at 12 months was 93.9%. Of the 782 eyes that were eligible for the uncorrected visual acuity (UCVA) analysis of effectiveness at the 6-month stability time point, 98.3% were corrected to 20/40 or better, and 87.7% were corrected to 20/20 or better. Subjects who responded to a patient satisfaction questionnaire before and after LASIK reported the following visual symptoms at a “moderate” or “severe” level at least 1% higher at 3 months post-treatment than at baseline: visual fluctuations (28.6% vs. 12.8% at baseline).

Long term risks of LASIK for myopia with and without astigmatism have not been studied beyond 12 months.Hyperopia: The hyperopia clinical study included 290 eyes treated, of which 100 of 290 eligible eyes were followed for 12 months. Accountability at 3 months was 95.2%, at 6 months was 93.9%, and at 12 months was 69.9%. Of the 212 eyes that were eligible for the UCVA analysis of effectiveness at the 6-month stability time point, 95.3% were corrected to 20/40 or better, and 69.4% were corrected to 20/20 or better. Subjects who responded to a patient satisfaction questionnaire before and after LASIK reported the following visual symptoms as “much worse” at 6 months post-treatment: halos (6.4%); visual fluctuations (6.1%); light sensitivity (4.9%); night driving glare (4.2%); and glare from bright lights (3.0%).

Long term risks of LASIK for hyperopia with and without astigmatism have not been studied beyond 12 months.Mixed Astigmatism: The mixed astigmatism clinical study included 162 eyes treated, of which 111 were eligible to be followed for 6 months. Accountability at 1 month was 99.4%, at 3 months was 96.0%, and at 6 months was 100.0%. Of the 142 eyes that were eligible for the UCVA analysis of effectiveness at the 6-month stability time point, 97.3% achieved acuity of 20/40 or better, and 69.4% achieved acuity of 20/20 or better. Subjects who responded to a patient satisfaction questionnaire before and after LASIK reported the following visual symptoms at a “moderate” or “severe” level at least 1% higher at 3 months post-treatment than at baseline: sensitivity to light (52.9% vs. 43.3% at baseline); visual fluctuations (43.0% vs. 32.1% at baseline); and halos (42.3% vs. 37.0% at baseline).

Long term risks of LASIK for mixed astigmatism have not been studied beyond 6 months. Wavefront-Guided Myopia: The wavefront-guided myopia clinical study included 374 eyes treated; 188 with wavefront-guided LASIK (Study Cohort) and 186 with Wavefront Optimized® LASIK (Control Cohort). 166 of the Study Cohort and 166 of the Control Cohort were eligible to be followed at 6 months. In the Study Cohort, accountability at 1 month was 96.8%, at 3 months was 96.8%, and at 6 months was 93.3%. In the Control Cohort, accountability at 1 month was 94.6%, at 3 months was 94.6%, and at 6 months was 92.2%.

Of the 166 eyes in the Study Cohort that were eligible for the UCVA analysis of effectiveness at the 6-month stability time point, 99.4% were corrected to 20/40 or better, and 93.4% were corrected to 20/20 or better. Of the 166 eyes in the Control Cohort eligible for the UCVA analysis of effectiveness at the 6-month stability time point, 99.4% were corrected to 20/40 or better, and 92.8% were corrected to 20/20. In the Study Cohort, subjects who responded to a patient satisfaction questionnaire before and after LASIK reported the following visual symptoms at a “moderate” or “severe” level at least 1% higher at 3 months post-treatment than at baseline: light sensitivity (47.8% vs. 37.2% at baseline) and visual fluctuations (20.0% vs. 13.8% at baseline). In the Control Cohort, the following visual symptoms were reported at a “moderate” or “severe” level at least 1% higher at 3 months post-treatment than at baseline: halos (45.4% vs. 36.6% at baseline) and visual fluctuations (21.9% vs. 18.3% at baseline). Long term risks of wavefront-guided LASIK for myopia with and without astigmatism have not been studied beyond 6 months.Topography-Guided Myopia: The topography-guided myopia clinical study included 249 eyes treated, of which 230 eyes were followed for 12 months. Accountability at 3 months was 99.2%, at 6 months was 98.0%, and at 12 months was 92.4%. Of the 247 eyes that were eligible for the UCVA analysis at the 3-month stability time point, 99.2% were corrected to 20/40 or better, and 92.7% were corrected to 20/20 or better. Subjects who responded to a patient satisfaction questionnaire before and after LASIK reported the following visual symptoms as “marked” or “severe” at an incidence greater than 5% at 1 month after surgery: dryness (7% vs. 4% at baseline) and light sensitivity (7% vs. 5% at baseline). Visual symptoms continued to improve with time, and none of the visual symptoms were rated as being “marked” or “severe” with an incidence of at least 5% at 3 months or later after surgery.Long term risks of topography-guided LASIK for myopia with and without astigmatism have not been studied beyond 12 months.Information for Patients: Prior to undergoing LASIK surgery with a WaveLight® Excimer Laser System, prospective patients must receive a copy of the relevant Patient Information Booklet, and must be informed of the alternatives for correcting their vision, including (but not limited to) eyeglasses, contact lenses, photorefractive keratectomy, and other refractive surgeries.

Attention: Please refer to a current WaveLight® Excimer Laser System Procedure Manual for a complete listing of the indications, complications, warnings, precautions, and side effects.

*Trademarks are property of their respective owners.

© 2016 Novartis 8/16 US-WVL-15-E-0287(1)

100697 US-WVL-15-E-0287(1) FP.indd 2 1/31/18 7:54 AM


“IT’S ALL REFRACTIVE SURGERY”

8:00–9:45 a .m . Session 1: Refractive Corneal Surgery: From Good to Great

Moderators: D. Rex Hamilton, MD, Elizabeth Yeu, MD

Panel: Kendall Donaldson, MD, Gregory D. Parkhurst, MD, Steve Slade, MD, William Willey, MD,

8:00 - 8:03 a.m. Introduction John A. Vukich, MD

8:03 - 8:08 a.m. The American Refractive Surgical Council and the Role of Social Media and Refractive Surgery Lianna Miller

8:08 - 8:15 a.m. Corneal Topography: What Should I be Looking for and What Should I be Worried About William B. Trattler, MD

8:15 - 8:18 a.m. Panel Discussion

8:18 - 8:25 a.m. Can We Eliminate the Risk of Ectasia? Steven Schallhorn, MD


8:28 - 8:35 a.m. How I Diagnose Dry Eye Disease Marjan Farid, MD


8:38 - 8:45 a.m. Managing the Ocular Surface for the Refractive Surgery Patient Edward J. Holland, MD


8:48 - 8:56 a.m. 5 Pearls for PRK Neel Desai, MD


8:59 - 9:07 a.m. 5 Pearls for LASIK Lou Probst, MD


9:10 - 9:18 a.m. 5 Pearls for SMILE John Doane, MD


9:21 - 9:56 a.m. Case Studies in Refractive Surgery Eric Donnenfeld, MD

9:56 - 10:10 a.m. BREAK

10:10–Noon Session II: Achieving Premium Results with Refractive Lens Surgery

Moderators: Rosa Braga-Mele, M.Ed, MD, FRCSC, and David F. Chang, MD

Panel: Graham Barrett, MD, Warren Hill, MD, Terry Kim, MD, Douglas D. Koch, MD, Julian Stevens, MD,

10:10 - 10:18 a.m. Premium Practice Starts at the Front Door Vance Thompson, MD


10:21 - 10:28 a.m. Using Advanced Technology to Improve Refractive Outcomes Daniel Chang, MD

10:28 – 10:31 a.m. Panel Discussion

10:31 - 10:39 a.m. Smart Software for Improving IOL Selection Kerry Solomon, MD


10:42 - 10:49 a.m. Can my Practice Afford Another High-tech Device? Matt Jensen, MBA


10:52 - 11:22 a.m. Case Studies in Refractive Cataract Surgery - Ask the Genius Bar David F. Chang, MD

REFRACTIVE DAY | AGENDA


11:22 - 11:27 a.m. Introduction of the Steinert Refractive Lecture April Steinert

11:27 - 11:42 a.m. The Steinert Refractive Lecture: Richard Lindstrom, MD

12:00 - 1:00 p.m. Lunch Break

1:00 - 2:50 p .m . Session III: Tips, Pearls, and Take-Home Messages

Moderators: Edward E. Manche, MD, Robert Weinstock, MD

Panel: Lance Kugler, MD, Sarah Nehls, MD, Sherman Reeves, MD, Mitchell Weikert, MD

1:00 - 1:10 p.m. Retina for Refractive Surgeons: Current Thinking on OCT and AMD Steve Charles, MD

1:10 - 1:15 p.m. Panel Discussion

1:15 - 1:50 p.m. My Favorite Refractive Tip

Panel: Jennifer Loh, MD, Cathleen McCabe, MD, Greg Parkhurst, MD, Karl Stonecipher, MD, Toby Tyson, MD, John A. Vukich, MD, Blake Williamson, MD, Roger Zaldivar, MD

1:50 - 1:57 p.m. How to Prevent and Manage Negative Dysphotopsia Nicole Fram, MD


2:00 - 2:07 p.m. Clear Lens, Not So Clear Lens, and Cataracts: Decision Making and Documentation George Waring IV, MD


2:10 - 2:17 p.m. Refractive Enhancements Following Cataract Surgery Kathryn Hatch, MD


2:20 - 2:27 p.m. Astigmatism Fix: When and How to Reposition a Toric IOL John P. Berdahl, MD


2:30 - 2:37 p.m. How to Perform an IOL Exchange When All Else Fails Steven G. Safran, MD


2:50-3:10 p.m. Break

3:10 - 4:30 p .m . Session IV: Choosing and Using the Right IOL

Moderators: Bonnie Henderson, MD, Nick Mamalis, MD

Panel: Sumit (Sam) Garg, MD, Preeya Gupta, MD, Richard Hoffman, MD, Michael Patterson, MD

3:10 - 3:17 p.m. Choosing the Right Implant: Rethinking the Dell Questionnaire Steven Dell, MD


3:20 - 3:27 p.m. Can We Make the Hill RBF and Barrett II Even More Accurate? Adi Abulafia, MD


3:30 - 3:37 p.m. Multifocal and Extended Depth of Focus IOLs Tal Raviv, MD


3:40 - 4:20 p.m. Case Studies in IOL selection Robert Cionni, MD

4:20 - 4:27 p.m. Bilateral Immediate Sequential Cataract Surgery Kent Stiverson, MD


4:30 p.m. Conclusion

REFRACTIVE DAY | AGENDA


PROGRAM CHAIRSRosa Braga-Mele, M.Ed, MD, FRCSCOntario, Canada

Eric D. Donnenfeld, MDRoslyn, New York

John A. Vukich, MDMadison, Wisconsin

SESSION MODERATORSDavid F. Chang, MDLos Altos, California

D. Rex Hamilton, MDLos Angeles, California

Bonnie An Henderson, MDBoston, Massachusetts

Nick Mamalis, MDSalt Lake City, Utah

Edward E. Manche, MDPalo Alto, California

Robert J. Weinstock, MDLargo, Florida

Elizabeth Yeu, MDNorfolk, Virginia

SESSION PANELISTSGraham D. Barrett, MIBBS, FRANZCOCity Beach, Australia

Kendall E. Donaldson, MDFort Lauderdale, Florida

Sumit (Sam) Garg, MDIrvine, California

Preeya K. Gupta, MDDurham, North Carolina

Warren E. Hill, MDMesa, Arizona

Richard S. Hoffman, MDEugene, Oregon

Terry Kim, MDDurham, North Carolina

Douglas D. Koch, MDHouston, Texas

Lance J. Kugler, MDOmaha, Nebraska

Sarah M. Nehls, MDMadison, Wisconsin

Gregory D. Parkhurst, MDSan Antonio, TexasMichael Patterson, DO Crossville, Tennessee

Sherman W. Reeves, MDMinnetonka, Minnesota

Stephen G. Slade, MDHouston, Texas

Julian D. Stevens, MDLondon, United Kingdom

Mitchell P. Weikert, MDHouston, Texas

William F. Wiley, MDBrecksville, Ohio

INVITED SPEAKERSAdi Abulafia, MDTel-Aviv, Israel

John P. Berdahl, MDSioux Fall, South Dakota

Daniel H. Chang, MDBakersfield, California

Steve Charles, MDGermantown, Tennessee

Robert J. Cionni, MDSalt Lake City, Utah

Steven J. Dell, MD Austin, Texas

Neel R. Desai, MDLargo, Florida

John F. Doane, MDKansas City, Missouri

Marjan Farid, MD Irvine, CA

Nicole R. Fram, MDLos Angeles, California

Kathryn M. Hatch, MD Boston, Massachusetts

Edward J. Holland, MD Cincinnati, Ohio

Matt Jensen, MBA Sioux Falls, South Dakota

Richard L. Lindstrom, MDMinneapolis, Minnesota

Jennifer Loh, MDMiami, Florida

Cathleen M. McCabe, MDBradenton, Florida

Liana MillerIrvine, California

Gregory D. Parkhurst, MDSan Antonio, Texas

Louis E. Probst, MD Ann Arbor, Michigan

Tal Raviv, MDNew York, New York

Steven G. Safran, MDLawrence Township, New Jersey

Steven C. Schallhorn, MDSan Diego, California

Kerry D. Solomon, MD Mount Pleasant, South Carolina

April SteinertIrvine, California

Richard Kent Stiverson, MDLone Tree, Colorado

Karl G. Stonecipher, MDGreensboro, North Carolina

Vance Thompson, MDSioux Falls, South Dakota

William B. Trattler, MDMiami, Florida

Farrell “Toby” Tyson, MDCape Coral, Florida

George Waring IV, MDMount Pleasant, South Carolina

Blake Williamson, MDBaton Rouge, Louisiana

Roger Zaldivar, MD Mendoza, Argentina

REFRACTIVE DAY | FACULTY

REFRACTIVE DAYASCRS gratefully acknowledges the

unrestricted educational grants received in support of this program from:


ALLERGAN

JOHNSON & JOHNSON VISION

CARL ZEISS MEDITEC



Target AudienceComprehensive ophthalmologists; refractive, cataract, and corneal surgeons who are performing cataract and refractive surgery.


• Identify refractive surgery screening and treatment options and list surgical technique adjustments to improve outcomes

• Analyze the role of advanced technology within refractive lens surgery

• Incorporate alternative or new approaches to manage risks and complications

• Evaluate lens-based treatment options to maximize patient satisfaction

Accreditation StatementThe American Society of Cataract and Refractive Surgery is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. ASCRS takes responsibility for the content, quality, and scientific integrity of this CME activity.




Note: All attendees must have their badges printed onsite to be verified as eligible for credit. The program evaluation and credit claim will be available online.


The program evaluation and CME credit claim will be available electronically. You can visit the Connect & Claim stations in the convention to complete the 2018 ASCRS Refractive Day course evaluation and credit claim. When complete, a certificate of the continuing education credits/hours can be printed.




REFRACTIVE DAY | CONTINUING MEDICAL EDUCATION


















REFRACTIVE DAY | FINANCIAL INTEREST INDEX


Abulafia, Adi Haag-Streit A Hoya A Physiol A

Barrett, Graham D. Alcon Laboratories, Inc. P, A Carl Zeiss Meditec P, A Clarity P Haag Streit P Oculus P Santec P Tomey P Topcon P Veracity P

Berdahl, John P. Alcon Laboratories, Inc. A, E Allergan A, E Aurea Medical A Avedro B Bausch + Lomb A Calhoun / Rxsight A Clarvista A Dakotasight Eye And Tissue Bank A Digisight R, A Envisia A Equinox P, R, A Glaukos A, E Iantech P, A Imprimis P, A Johnson & Johnson Vision A New World Medical A, E Ocular Surgical Data R, A Ocular Theraputix A Omega Ophthalmic R, A Sightlife Surgical R, A Vance Thompson Vision R, A, Y Veracity R, A Vittamed A

Braga-Mele, Rosa M. Alcon Laboratories, Inc. A Allergan A Johnson & Johnson Vision A

Chang, Daniel H. Allergan A Carl Zeiss Meditec A, B, E Clarvista Medical A Johnson & Johnson Vision A, B, D, E Mynosys Cellular Devices A, D Omega Ophthalmics R, A

Chang, David F. None

Charles, Steve Alcon Laboratories, Inc. P, A, E

Cionni, Robert Alcon Laboratories, Inc. A, B, D, E Clarvista A Mile High R, A Morcher P Ocumetics R Omeros R, B Revision Optics D

Dell, Steven J. Advanced Tear Diagnostics A Allergan A Bausch + Lomb A Johnson & Johnson Vision A Lumenis A Optical Express A Presbyopia Therapies R, A Tracey Technologies R, A

Desai, Neel Alcon Laboratories, Inc. R, A, B, D Allergan, Inc. R, A, B, D Biotissue, Inc. R, A, B, D Lensar, Inc. A, B Valeant R, A, B, D

Doane, John F. Calhoun Vision D Carl Zeiss Meditec A, D Presbyopia Therapies R

Donaldson, Kendall E. Alcon Laboratories, Inc. A Allergan A Bausch + Lomb A Biotissue A Johnson & Johnson Vision A Novabay A Omeros A Shire A Sun Pharmaceuticals A TearLab A

Donnenfeld, Eric D. Acufocus A Alcon Laboratories, Inc. A Allergan A Aquesys R, A, B, D Autofocus R, A, B, D Avedro R, A, B, D Bausch + Lomb A Beaver-Visitec Elenza A CRST A Elenza R, A, B, D Foresight A Glaukos R, A, B, D Icon Biosciences A Johnson & Johnson Vision A Kala A Katena R, A, B, D Lensgen R, A, B, D Mati Pharmaceuticals R, A, B, D Merck A Mimetogen R, A, B, D Novabay R, A, B, D Novaliq A Ocuhub R, A, B, D Odyssey A Omega Ophthalmics A Oys A Pogotec R, A, B, D Rps R, A, B, D Sarcode R, A, B, D Strathspey Crown R, A, B, D TearLab R, A, B, D Truevision R, A, B, D Veracity R, A, B, D Versant Ventures R, A, B, D Visionary Ventures R, A, B, D



Farid, Marjan Allergan A Johnson & Johnson Vision A, B Shire A, B SightLife Surgical A, B TearScience A

Fram, Nicole R. Accutome, Inc D Alcon Laboratories, Inc. A, B Allergan A B & L/Valeant B Carl Zeiss Meditec A Johnson & Johnson Vision A, B Notal Vision Inc. A Ocular Science R, A Omeros A Rxsight, Inc. A Shire A, B Sightlife Surgical R, A Sun Pharmaceutical A

Garg, Sumit (Sam) Aerie A Carl Zeiss Meditec A Ivantis A Johnson & Johnson A, B Kala Pharmaceuticals A Ocutrx A Revision Optics A Rps R Rxsight A Rysurg A Shire A, B Sightlife Surgical A TearScience A Visioncare A

Gupta, Preeya K. Alcon Laboratories, Inc. A Allergan A Aurea A Biotissue A J & J Vision A Novabay A Ocular Science A Shire A TearLab A TearScience A

Hamilton, D. Rex Carl Zeiss Meditec B, E Johnson & Johnson Vision B, E

Hatch, Kathryn M. Avedro A Omeros A Shire A

Henderson, Bonnie An Alcon Laboratories, Inc. A, B Allergan A Johnson & Johnson Vision A Novartis A, B Shire A Sun Pharmaceuticals A

Hill, Warren E. Alcon Laboratories, Inc. A Carl Zeiss Meditec A Haag-Streit Switzerland P, A, D Omega R, A Veracity Surgeical A

Hoffman, Richard S. Carl Zeiss Meditec A Microsurgical Technology/MST A

Holland, Edward J. Alcon Laboratories, Inc. A, B, D, E Allergan A, B, D Kala Corporation A Mati Therapeutics A, D Omeros A, B, D PRN A, D Senju Pharmaceuticals A, B, D Shire A, B TearLab A TearScience A, B

Jensen, Matt Carl Zeiss Meditec A Eye Care Leaders A Eyebrain Medical A Johnson & Johnson Vision A Microsurgical Technologies A Ocular Science A Physician Recommended Nutriceuticals A TearScience A Visiometrics A

Kim, Terry Aerie Pharmaceutical A

Koch, Douglas D. Alcon Laboratories, Inc. A Carl Zeiss Meditec A Ivantis R Johnson & Johnson Vision A Perfect Lens A Powervision R

Kugler, Lance Acufocus A Alphaeon R Johnson & Johnson Vision A

Lindstrom, Richard L. Acufocus A Advanced Refractive Technologies A Alcon Laboratories, Inc. A Allergan A Alphaeon R, A Argoshield R, A Augustine Temperature Management R Aviana R, A Bausch + Lomb P, R, A Belkin Laser R, A Biosyntrx R Broadspot R, A Bruder R Carl Zeiss Meditec A Checked-Up R, A Clarity Ophthalmics R, A Clear Sight R, A Confluence Acquisition Partners, Inc. R Cxi, Esi R, A Dose R, A E-Vision Medical Devices R E-Vision Photography R, A Ebv Partners R, A Egg Basket Ventures R, A Egg Factory R Elenza R, A Equinox R, A Excel-Lens, Inc. R



Eyemaginations, Inc. R, A Flying L Ventures R, A Forsight Vision 3 R, A Forsight Vision 6 R, A Fziomed, Inc. R G.Nano R Glaukos R, A Healthcare Transaction Services R, A High Performance Optics R Iantech R, A Idoc, Inc. R Iicayr R, A Imprimis R, A Innovega R Intellinet R Johnson & Johnson Vision R, A Kalarx Pharmaceuticals R, A King Pharma R Lenticular Research Group R Lifeguard Health R, A Lumineyes R Minnesota Eye Consultants R, A NASA-Vision For Mars Program A Nicox A Novabay R, A Ocular Optics R, A Ocular Surgery News A Ocular Therapeutix R, A Oculatec R Omega Eye Health R, A Omega Ophthalmics R, A Omeros CorP, A Pogotec R Qsensei R Quest R, A Refractec R, A Schroeder Ventures Fund Ii,Iii,Iv,Vi R, A Sightlife Surgical R, A Sightpath R, A Silk Technologies C Solbeam, Inc. R Strathsprey Crown R Stroma R Sun Pharmaceuticals A Tearclear C TearLab R, A TearScience R Tissue Tech R

Tracey Technologies R, A True Vision R, A Versant R, A Viradax R Vision Solutions Technology R, A Visionary Ventures R, A Wf Systems R

Loh, Jennifer M. Allergan A Johnson & Johnson Vision A Shire B Sun Pharmaceuticals B

Mamalis, Nick Advanced Vision Science D Alcon Laboratories, Inc. D Anew Optics A, D Carl Zeiss Meditec D Clarvista Medical D Coda Therapeutics D Cord D Genisphere D Hoya D Lensgen D Medicontur D Mynosys D Omega D Perfectlens D Powervision D Sharklet D Shifamed D

Manche, Edward E. Allergan, Inc. D Avedro, Inc. A Avellino Laboratories D Calhoun Vision R Carl Zeiss Meditec A, D Johnson & Johnson Vision A, D Krypton Vision, Inc. R, A Ocular Therapeutix, Inc. D Presbia, Inc. D Seros Medical, LLC R

McCabe, Cathleen M. Alcon Laboratories, Inc. B, D Allergan B Bausch + Lomb B Glaukos B, D Ivantis B, D Omeros B Shire B Miller, Liana Tear Film Innovations A

Nehls, Sarah None

Parkhurst, Gregory D. Carl Zeiss Meditec B, E Glaukos A, D Johnson & Johnson Vision D Lensar B Revision Optics B, D, E STAAR Surgical B, E Patterson, Michael D. New World Medical A Probst, Louis E. None Raviv, Tal Bausch + Lomb B Glaukos A Johnson & Johnson Vision A, B Ocular Therapeutix A, B Shire B Reeves, Sherman W. Avedro A Johnson & Johnson Vision B Safran, Steven G. Cynosure B Diopsys A



Schallhorn, Steven C. Acufocus A Carl Zeiss Meditec Z Slade, Stephen G. Alcon Laboratories, Inc. A Bausch + Lomb A Carl Zeiss Meditec A Clarity A Johnson & Johnson Vision A Novartis R RVO R

Solomon, Kerry D. Alcon Laboratories, Inc. A, B, C, D, E Allergan R, A, B, C Aquesys R, A, B, C Bausch + Lomb D Clarvista Medical A, B, C Glaukos R, A, B, C Icon Biosciences D Imprimis D Integrity Digital Solutions R, A, B, C Johnson & Johnson Vision A, B, C Lenstec D Mati Therapeutics R Octane Visionary Vc Fund R Ocuhub R Omeros Corp R Pogotec R PRN R, A, B, C TearLab R TearScience D Veracity Innovative R Versuant R Wavetec A, B, C, D, E

Steinert, April None

Stevens, Julian D. Johnson & Johnson Vision A Oculentis Ag P Revision Optics Inc. A STAAR Surgical A Vista Optical Inc. A Stiverson, Kent None Stonecipher, Karl G. Alcon Laboratories, Inc. A, B, D Allergan A, B, D, E Bausch + Lomb A, B, D, E Johnson & Johnson Vision B Thompson, Vance Acufocus A, D Alcon Laboratories, Inc. A, D Allergan A, D Allotex A Avellino A, D Bausch + Lomb A, D Carl Zeiss Meditec A, D Equinox R, A Euclid Systems, Inc. A Eyebrain Medical, Inc. R Eyegate Pharma A, D Imprimis A Johnson & Johnson A, D Mynosys, Inc. R, A, D Novartis D Oculeve R, A Ophtec, Inc. A, D Precision Lens A Rxsight A, D Tarsus Rx A Treehouse Eyes R, A Vivor Ag A, D

Trattler, William B. Alcon Laboratories, Inc. A Allergan A, B, D Alphaeon R Arcscan R Avedro A, B Bausch + Lomb A, B Cxlo R Johnson & Johnson Vision A, B Novabay B Shire A, B Sun Pharmaceuticals A, B Tyson, Farrell C. Alcon Laboratories, Inc. D Bausch + Lomb B, D Johnson & Johnson Vision B, D Vukich, John A. Acufocus B Carl Zeiss Meditec A Johnson & Johnson Vision B STAAR Surgical R, A Waring, George O. Ace Vision A Acufocus A Alcon Laboratories, Inc. A, S Allergan A, E, S Avedro A Bausch + Lomb A, S Glasses Off A Johnson & Johnson Vision A Omega Ophthalmics A Perfect Lens A Visiometrics R, A Weikert, Mitchell P. Sentiss Pharmaceuticals A



Weinstock, Robert J. Alcon Laboratories, Inc. A, B Bausch + Lomb A, B, E Doctors Allergy R Health-E R Johnson & Johnson Vision A, E Lensar R, A Omeros A Pogotec R Rps R Rxsight R STAAR Surgical R, A Sun Pharmaceuticals A, B, E Tissuetech R Truevision R, A Ubeam R Wiley, William F. Acufocus A Alcon Laboratories, Inc. B Allergan D Arcscan A Calhoun D Carl Zeiss Meditec A Clarity R Equinox R Glaukos A Imprimis P Johnson & Johnson Vision A, B, D New World Medical A Omega R, A Revision B Rxsight R, B, D

Williamson, Blake Alcon Laboratories, Inc. A, B Allergan B Bausch + Lomb B Biotissue A, B Diopsys A, B Glaukos A, B Johnson & Johnson Vision A, B New World Medical A, B, D Yeu, Elizabeth Alcon Laboratories, Inc. A, B Allergan A, B Bausch + Lomb A Biotissue A, B, D Bvi A Ioptics A, B, D Johnson & Johnson Vision A, B Kala A, D Modernizing Medicine R Ocular Science R, D Ocular Therapeutix A Ocusoft A Omeros A Science Based Health A Shire A, B TearLab A, B, D TearScience A Topcon D Zaldivar, Roger Acufocus E Johnson & Johnson E Visiometrics E

REFRACTIVE DAY

EXHIBITORS

ASCRSGlaucomaDay.com | ASCRSrefractiveday.org | corneaday.org

FRIDAY APRIL 13 | 7:00 a.m. – 4:00 p.m.

ASCRS REFRACTIVE DAY

BALLROOM PRE-FUNCTION 1

BALLROOM PRE-FUNCTION 2

CORNEA DAY

10 11 12 13 14 15 16 17 18 20 21 22 23 24

30

25

35 34 3332 31

29

26 27 28191 2 3 4 5 6 7 8

41 40 39 38 37 36

9

Glaucoma Day is located on Level 2, Room 207 AB .


Aerie Pharmaceutical, Inc. TT6

Alcon TT19

Allergan TT34

Allergan Surgical TT35

Bausch + Lomb TT10

Beaver-Visitec International, Inc. TT3

Bio-Tissue TT31

CareCredit TT32

CorneaGen (formerly known as SightLife Surgical) TT33

Cornea Society TT7

Diopsys TT15

Ellex TT11

Geisinger TT5

Glaukos Corporation TT36

Haag-Streit USA TT4

Icare Tonometers TT24

IRIDEX TT38

Kaiser Permanente TT41

Konan Medical USA TT21

Lions Eye Institute for Transplant & Research TT23

Lumenis-Vision TT8

Mallinckrodt Pharmaceuticals TT13

New World Medical TT9

NovaBay Pharmaceuticals, Inc. TT18

Novartis Pharmaceuticals TT39

OCULUS, Inc. TT17

OCuSOFT, Inc. TT37

San Diego Eye Bank TT12

Shire TT16

Sight Sciences TT40

STAAR Surgical TT22

Vision Share TT14

Zeiss TT20

COMPANY TT# COMPANY TT#

EXHIBITORS


NOTES

sking

Sticky Note

Marlyn -- if it's not too much work to make this page a Notes page, fine. If it's a pain in the arse, don't bother. Thanks!

© 2018 Novartis 2/18 US-CYP-18-E-0312

CyPass® ULTRA Micro-StentIMPORTANT PRODUCT INFORMATION

CAUTION: FEDERAL (USA) LAW RESTRICTS THIS DEVICE TO SALE BY OR ON THE ORDER OF A PHYSICIAN. INDICATION: The CyPass® ULTRA Micro-Stent is indicated for use in conjunction with cataract surgery for the reduction of intraocular pressure (IOP) in adult patients with mild to moderate primary open-angle glaucoma (POAG).

CONTRAINDICATIONS: Use of the CyPass® ULTRA Micro-Stent is contraindicated in the following circumstances or conditions: (1) in eyes with angle closure glaucoma; and (2) in eyes with traumatic, malignant, uveitic or neovascular glaucoma or discernible congenital anomalies of the anterior chamber angle.

MRI INFORMATION: The CyPass® ULTRA Micro-Stent is magnetic resonance (MR) Safe: the implant is constructed of polyimide material, a non-conducting, non-metallic, non-magnetic polymer that poses no known hazards in all magnetic resonance imaging environments.

WARNINGS: Gonioscopy should be performed prior to surgery to exclude peripheral anterior synechiae (PAS), rubeosis, and other angle abnormalities or conditions that would prohibit adequate visualization of the angle that could lead to improper placement of the stent and pose a hazard.

PRECAUTIONS: The surgeon should monitor the patient postoperatively for proper maintenance of intraocular pressure. The safety and effectiveness of the CyPass® ULTRA Micro-Stent has not been established as an alternative to the primary treatment of glaucoma with medications, in patients 21 years or younger, in eyes with significant prior trauma, chronic inflammation, eyes with an abnormal anterior segment, eyes with chronic inflammation, eyes with glaucoma associated with vascular disorders, pseudophakic eyes with glaucoma, eyes with uveitic glaucoma, eyes with pseudoexfoliative or pigmentary glaucoma, eyes with other secondary open angle glaucomas, eyes that have undergone prior incisional glaucoma surgery or cilioablative procedures, eyes with laser trabeculoplasty performed ≤ 3 months prior to the surgical screening visit, eyes with unmedicated IOP less than 21 mmHg or greater than 33 mmHg, eyes with medicated IOP greater than 25 mmHg, in the setting of complicated cataract surgery with iatrogenic injury to the anterior or posterior segment, and when implantation is without concomitant cataract surgery with IOL implantation for visually significant cataract. The safety and effectiveness of use of more than a single CyPass® ULTRA Micro-Stent has not been established.

ADVERSE EVENTS: In a randomized, multicenter clinical trial comparing cataract surgery with CyPass® ULTRA Micro-Stent to cataract surgery alone, the most common post-operative adverse events included: BCVA loss of 10 or more letters at 3 months after surgery (8.8% for CyPass® vs. 15.3% for cataract surgery only); anterior chamber cell and flare requiring steroid treatment 30 or more days after surgery (8.6% vs. 3.8%); worsening of visual field mean deviation by 2.5 or more decibels (6.7% vs. 9.9%); IOP increase of 10 or more mmHg 30 or more days after surgery (4.3% vs. 2.3%); and corneal edema 30 or more days after surgery, or severe in nature (3.5% vs. 1.5%).

ATTENTION: PLEASE REFER TO THE PRODUCT INSTRUCTIONS FOR A COMPLETE LIST OF CONTRAINDICATIONS, WARNINGS, PRECAUTIONS AND ADVERSE EVENTS.

100840 US-CYP-18-E-0312_PI GDFP.indd 1 2/14/18 3:16 PM

ONE CYPASS® MICRO-STENT IS ALL IT TAKES TO CONNECTTO SAFE, CONSISTENT, LONG-TERM IOP CONTROL

and done

© 2018 Novartis 2/18 US-CYP-18-E-0312

FOR AN EXPERIENCE LIKE NO OTHER, CONNECT WITH AN ALCON REPRESENTATIVE TODAY.

IN THE COMPASS STUDY AT TWO YEARS1,2:• 72.5% of patients achieved a ≥20% reduction in IOP (n=374)• 93% of responders were medication free*• Safety profi le similar to cataract surgery alone

References: 1. CyPass® Micro-Stent Instructions for Use. 2. Vold S, Ahmed IIK, Craven ER, et al. Two-year COMPASS trial results: supraciliary microstenting with phacoemulsifi cation in patients with open-angle glaucoma and cataracts. Ophthalmology. 2016;123(10):2103-2112.

FOR THE REDUCTION OF IOP IN MILD TO MODERATE PRIMARYOPEN-ANGLE GLAUCOMA AT THE TIME OF CATARACT SURGERY

*Those patients who attained an unmedicated mean diurnal IOP reduction of 20% or more as compared to baseline in the absence of IOP-a� ecting surgery during the study.

and done

NOWNOWAVAILABLE

US-CYP-18-E-0312 ASize.indd 1 2/20/18 10:25 AM

view the 2018 final subspecialty day program -...

Documents